IN2015DN01967A - - Google Patents

Info

Publication number
IN2015DN01967A
IN2015DN01967A IN1967DEN2015A IN2015DN01967A IN 2015DN01967 A IN2015DN01967 A IN 2015DN01967A IN 1967DEN2015 A IN1967DEN2015 A IN 1967DEN2015A IN 2015DN01967 A IN2015DN01967 A IN 2015DN01967A
Authority
IN
India
Prior art keywords
antibody
compared
reduced immunogenicity
anti tnf
reference antibody
Prior art date
Application number
Inventor
Fiona A Harding
Olivia Jennifer Razo
Original Assignee
Abbvie Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Biotherapeutics Inc filed Critical Abbvie Biotherapeutics Inc
Publication of IN2015DN01967A publication Critical patent/IN2015DN01967A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

The disclosure describes methods of identifying a variant of a reference antibody with reduced immunogenicity as compared to the reference antibody. The disclosure further describes variants of a reference anti TNF a antibody having reduced immunogenicity as compared to the reference anti TNF a reference antibody.
IN1967DEN2015 2012-09-19 2013-09-18 IN2015DN01967A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261703170P 2012-09-19 2012-09-19
PCT/US2013/060480 WO2014047222A2 (en) 2012-09-19 2013-09-18 Methods for identifying antibodies with reduced immunogenicity

Publications (1)

Publication Number Publication Date
IN2015DN01967A true IN2015DN01967A (en) 2015-08-14

Family

ID=49304336

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1967DEN2015 IN2015DN01967A (en) 2012-09-19 2013-09-18

Country Status (27)

Country Link
US (1) US9279016B2 (en)
EP (2) EP3211006A3 (en)
JP (1) JP2015537190A (en)
KR (1) KR20150056788A (en)
CN (1) CN104704000A (en)
AU (1) AU2013318147B2 (en)
BR (1) BR112015005857A2 (en)
CA (1) CA2885422A1 (en)
CY (1) CY1118893T1 (en)
DK (1) DK2897978T3 (en)
ES (1) ES2621285T3 (en)
HK (1) HK1211306A1 (en)
HR (1) HRP20170937T1 (en)
HU (1) HUE032569T2 (en)
IL (1) IL237833A0 (en)
IN (1) IN2015DN01967A (en)
LT (1) LT2897978T (en)
MX (1) MX2015003541A (en)
NZ (1) NZ705606A (en)
PL (1) PL2897978T3 (en)
PT (1) PT2897978T (en)
RS (1) RS56093B1 (en)
RU (1) RU2648141C2 (en)
SG (1) SG11201502094TA (en)
SI (1) SI2897978T1 (en)
TW (1) TWI519646B (en)
WO (1) WO2014047222A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478802B (en) * 2016-10-11 2019-08-09 浙江省人民医院 TNF-α protein B cell epitope, multiple antigenic peptide and application containing this epitope
TW202039554A (en) * 2018-12-19 2020-11-01 瑞士商諾華公司 Anti-tnf-alpha antibodies
WO2021005607A1 (en) * 2019-07-09 2021-01-14 National Institute For Biotechnology In The Negev Ltd. Antibodies with reduced immunogenicity
AU2020360849A1 (en) 2019-09-30 2022-04-14 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Protein binders to iRhom2 epitopes
FR3104582A1 (en) * 2019-12-17 2021-06-18 Commissariat A L'energie Atomique Et Aux Energies Alternatives Adalimumab variants with reduced immunogenic potential
CN113125714B (en) * 2019-12-31 2023-06-16 科美博阳诊断技术(上海)有限公司 Human immunodeficiency virus antibody detection kit and application thereof
WO2021147642A1 (en) * 2020-01-20 2021-07-29 Bio-Thera Solutions, Ltd. Methods, models and systems related to antibody immunogenicity
KR102568430B1 (en) * 2020-11-16 2023-08-24 바디텍메드(주) Rapid detection method of anti-drug antibody
AU2022229740A1 (en) 2021-03-01 2023-08-24 New York Society For The Relief Of The Ruptured And Crippled, Maintaining The Hospital For Special Surgery Humanized antibodies against irhom2
WO2022207652A1 (en) 2021-03-29 2022-10-06 Scirhom Gmbh Methods of treatment using protein binders to irhom2 epitopes
WO2022214664A1 (en) 2021-04-09 2022-10-13 Philogen S.P.A. Improved interferon-gamma mutant
WO2024023246A1 (en) 2022-07-28 2024-02-01 Philogen S.P.A. Antibody binding to pd1
WO2024033362A1 (en) 2022-08-08 2024-02-15 Atb Therapeutics Humanized antibodies against cd79b

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
DE3687170T2 (en) 1985-01-25 1993-04-01 Kitasato Inst ANTITUMORAL ANTIBIOTICS AND THEIR PRODUCTION.
US5264357A (en) 1985-05-24 1993-11-23 Genentech, Inc. Nucleic acids vectors and cells for the synthesis of membrane anchor fusion polypeptides
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
HU221984B1 (en) * 1996-02-09 2003-03-28 Basf Ag Human antibodies binding human tnfalfa, pharmaceutical compositions containing thereof and use thereof
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6787308B2 (en) 1998-07-30 2004-09-07 Solexa Ltd. Arrayed biomolecules and their use in sequencing
AR021833A1 (en) 1998-09-30 2002-08-07 Applied Research Systems METHODS OF AMPLIFICATION AND SEQUENCING OF NUCLEIC ACID
ATE384792T1 (en) 1998-11-18 2008-02-15 Genentech Inc ANTIBODY VARIANTS WITH HIGHER BINDING AFFINITIES COMPARED TO PARENTAL ANTIBODIES
US7211390B2 (en) 1999-09-16 2007-05-01 454 Life Sciences Corporation Method of sequencing a nucleic acid
WO2001023610A2 (en) 1999-09-29 2001-04-05 Solexa Ltd. Polynucleotide sequencing
US6686168B1 (en) 1999-11-04 2004-02-03 Zymogenetics, Inc. Cell surface display of proteins by recombinant host cells
UA81743C2 (en) * 2000-08-07 2008-02-11 Центокор, Инк. HUMAN MONOCLONAL ANTIBODY WHICH SPECIFICALLY BINDS TUMOR NECROSIS FACTOR ALFA (TNFα), PHARMACEUTICAL MIXTURE CONTAINING THEREOF, AND METHOD FOR TREATING ARTHRITIS
AU2001293163A1 (en) 2000-09-27 2002-04-08 Lynx Therapeutics, Inc. Method for determining relative abundance of nucleic acid sequences
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6956114B2 (en) 2001-10-30 2005-10-18 '454 Corporation Sulfurylase-luciferase fusion proteins and thermostable sulfurylase
US7057026B2 (en) 2001-12-04 2006-06-06 Solexa Limited Labelled nucleotides
US20030206898A1 (en) 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
AU2003283995A1 (en) 2002-09-30 2004-04-19 Protein Design Labs, Inc. Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes
BR122018071808B8 (en) 2003-11-06 2020-06-30 Seattle Genetics Inc conjugate
TW201705980A (en) * 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
WO2005123780A2 (en) 2004-04-09 2005-12-29 Protein Design Labs, Inc. Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
US7632497B2 (en) 2004-11-10 2009-12-15 Macrogenics, Inc. Engineering Fc Antibody regions to confer effector function
ES2340205T3 (en) 2005-11-12 2010-05-31 Eli Lilly And Company ANTI-EGFR ANTIBODIES.
MX2010002269A (en) 2007-08-28 2010-03-25 Abbott Biotech Ltd Compositions and methods comprising binding proteins for adalimumab.
WO2009059235A2 (en) 2007-11-01 2009-05-07 Facet Biotech Corporation Immunoglobulin display vectors
TWI559930B (en) 2009-04-16 2016-12-01 Abbvie Biotherapeutics Inc Anti-tnf-α antibodies and their uses
GB0909904D0 (en) * 2009-06-09 2009-07-22 Affitech As Product
KR20120138241A (en) * 2010-03-11 2012-12-24 화이자 인코포레이티드 Antibodies with ph dependent antigen binding
WO2012020038A1 (en) * 2010-08-13 2012-02-16 Roche Glycart Ag Anti-tenascin-c a2 antibodies and methods of use
CN103534268B (en) * 2010-10-20 2016-05-18 牛津生物疗法有限公司 Antibody

Also Published As

Publication number Publication date
ES2621285T3 (en) 2017-07-03
EP3211006A2 (en) 2017-08-30
CN104704000A (en) 2015-06-10
WO2014047222A3 (en) 2014-10-23
RU2648141C2 (en) 2018-03-22
WO2014047222A9 (en) 2014-06-26
RU2015111671A (en) 2016-11-10
EP3211006A3 (en) 2017-11-08
LT2897978T (en) 2017-06-12
PL2897978T3 (en) 2017-08-31
IL237833A0 (en) 2015-05-31
BR112015005857A2 (en) 2017-08-08
EP2897978A2 (en) 2015-07-29
US20140227251A1 (en) 2014-08-14
US9279016B2 (en) 2016-03-08
CA2885422A1 (en) 2014-03-27
SG11201502094TA (en) 2015-04-29
SI2897978T1 (en) 2017-05-31
AU2013318147A1 (en) 2015-03-19
AU2013318147B2 (en) 2018-01-04
EP2897978B1 (en) 2017-03-22
TW201418469A (en) 2014-05-16
CY1118893T1 (en) 2018-01-10
WO2014047222A2 (en) 2014-03-27
HUE032569T2 (en) 2017-09-28
KR20150056788A (en) 2015-05-27
NZ705606A (en) 2018-05-25
HK1211306A1 (en) 2016-05-20
DK2897978T3 (en) 2017-05-15
HRP20170937T1 (en) 2017-11-03
MX2015003541A (en) 2015-10-26
PT2897978T (en) 2017-05-22
RS56093B1 (en) 2017-10-31
JP2015537190A (en) 2015-12-24
TWI519646B (en) 2016-02-01

Similar Documents

Publication Publication Date Title
IN2015DN01967A (en)
IL271697A (en) Anti-cxcr3 antibodies
HK1206364A1 (en) Methods for improving diaphragm function
IN2014CN02639A (en)
IL228001B (en) Antibodies to cd70
AU2013316100A1 (en) Antibody evolution immunogens
EP2855529A4 (en) Humaneered anti-factor b antibody
EP2939244A4 (en) Fuel assembly
GB201207235D0 (en) Fuel pump assembly
ZA201406703B (en) Improved injections
GB201212703D0 (en) Transactional account repository
EP2695133A4 (en) Identifying similarity
GB201218066D0 (en) Optoelectronic assembly
LT2750136T (en) Fuel assembly
UA72478U (en) Use of polentar as frigoprotector
GB201210772D0 (en) Novel lighting methods
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
GB201202794D0 (en) Fuel economy patent abstract